Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact
parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and
tolerability of CTAP101 will also be evaluated